Peptides Vietnam LogoPeptides Vietnam
Back to Home
2026 Decision Hub

GLP-1 Vietnam 2026: 24.2% Body Weight Loss in 48 Weeks

GLP-1 drugs in Vietnam start with one number: retatrutide's phase 2 trial reported 24.2% average body weight reduction over 48 weeks, and its phase 3 TRIUMPH-1 trial, published in the New England Journal of Medicine in September 2026, reported -25.0% at the 12 mg trial dose versus -3.9% on placebo over 80 weeks for the treatment-regimen estimand (trial dose, not a recommendation). It's the GLP-1 nobody can buy at a Vietnamese pharmacy, because it isn't FDA-approved yet. So Vietnam's expat and biohacker scene imports it research-grade, alongside the two other incretin agonists that matter here, tirzepatide (22.5%, no Vietnamese marketing registration, so research-grade is the route that exists) and semaglutide (14.9%, intermittent Ozempic in District 1 and District 7 pharmacies [2]), plus cagrilintide (10%+ standalone, used mostly for stacking), which is an amylin analogue rather than a GLP-1.

Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026

In the Vietnam expat and biohacker scene, the research-grade route is the one people reach for when they want compounds that are not approved here yet. In other countries, doctors prescribe these or give them only in trials. Quality varies by supplier, so check the published certificate first. But the path requires homework: verifying COAs, understanding reconstitution, and choosing between single-agonist (semaglutide), dual-agonist (tirzepatide), and triple-agonist (retatrutide) compounds. This page compares the four most relevant weight-loss peptides for the Vietnam market, the three incretin agonists above plus the amylin analogue cagrilintide, and helps you pick; if you want to see how these compounds stack up against the wider field, this breakdown of peptides ranked for fat loss by trial effect size sets the clinical benchmarks. For legal status and city-by-city access inside the country, the GLP-1 Vietnam guide is the deeper reference. For the demand side, the Vietnam weight loss market guide covers the obesity data: overweight among Vietnamese 5 to 19 year olds rose from 8.5% in 2010 to 19% in 2020 and obesity from 2.5% to 8.1%, while no market-size figure checks out.

Disclaimer: this is general education, not medical advice and not a dosing recommendation.

On this page

Comparison Table

PeptideAvg Weight LossFDA StatusVietnam PharmacyResearch CostBest For
★RetatrutideWeight loss guide →24.2%Phase 3Not availableVaries, message Peptara LabsMaximum weight loss
TirzepatideWeight loss guide →22.5%FDA ApprovedNot registeredVaries, message Peptara LabsStrong results, FDA approved
SemaglutideWeight loss guide →15%FDA ApprovedOzempic intermittentVaries, message Peptara LabsLongest track record
Cagrilintide10%+Phase 3Not availableVaries, message Peptara LabsStacking with GLP-1

Research-grade prices vary by vial, so no monthly figure is shown for any of the four. Mounjaro holds no Vietnamese marketing registration, so there is no hospital price for it.

Which one should you choose?

Largest trial weight loss: Retatrutide. The triple-agonist mechanism (GLP-1 + GIP + glucagon) makes retatrutide the most powerful weight loss peptide studied in clinical trials to date. The Phase 2 results reported 24.2% average body weight reduction over 48 weeks, more than any dual-agonist or single-agonist compound in these studies.1 Early studies link the glucagon part to higher energy use. It has no FDA approval and is still in Phase 3 trials, so whether anyone should use it is a licensed prescriber's call. The retatrutide Vietnam 2026 guide covers pricing, sourcing, and legal status.

Want proven safety and the longest track record → Semaglutide.2 Semaglutide (Ozempic, Wegovy) has the longest track record of these four. In the STEP trials, average weight loss reached 14.9% at 68 weeks, and millions of people worldwide have used it since FDA approval in 2017 for diabetes and 2021 for obesity.2 The safety profile is well understood, the side effect management is documented, and it has been studied longer than any of the other three. In Vietnam, you have both the pharmacy route (Ozempic pens appear intermittently at pharmacies in HCMC and Hanoi) and the research-grade route. If you want to stick with the most proven compound, start with the semaglutide Vietnam 2026 guide.2

Want strong results with FDA approval → Tirzepatide. Tirzepatide (Mounjaro, Zepbound) is the sweet spot for many people. It's a dual-agonist (GLP-1 + GIP) that demonstrated 22.5% average weight loss in the SURMOUNT trials, significantly more than semaglutide but not quite as high as retatrutide. [3] The GIP agonism appears to reduce nausea compared to pure GLP-1 drugs, which makes tirzepatide easier to tolerate for some users. In Vietnam, Mounjaro holds no marketing registration, so there is no registered hospital or pharmacy route for it and no hospital price to quote. [4] Research-grade tirzepatide is widely available from peptide suppliers and is priced by vial rather than by month. If you want FDA-approved efficacy through the route that actually exists in Vietnam, read the tirzepatide Vietnam 2026 guide.

The Four Options Explained

Retatrutide

Retatrutide is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously,18 creating the most powerful metabolic shift of any weight loss compound ever studied. Phase 2 clinical trials showed 24.2% average body weight reduction over 48 weeks at the 12mg dose, and 83% of that group lost at least 15%.5 In Vietnam, retatrutide isn't available at any pharmacy or hospital, because it holds no marketing registration here,20 and it remains an investigational Phase 3 compound globally.19 The only route that exists in the country is research-grade supply from peptide sellers who ship with cold-chain logistics. The retatrutide Vietnam 2026 guide covers supplier verification, COA red flags, reconstitution protocols, and what expats need to know about legal status. Because it is still a Phase 3 trial medicine, whether it suits any one person is a question for their own prescriber.

Tirzepatide

Tirzepatide is a dual-agonist peptide that activates both GLP-1 and GIP receptors, delivering substantially more weight loss than single-agonist compounds while maintaining FDA approval and a strong safety profile. The SURMOUNT clinical trials demonstrated 22.5% average weight loss over 72 weeks at the 15mg dose, positioning tirzepatide between semaglutide and retatrutide in terms of efficacy.6 The GIP agonism appears to reduce GLP-1-driven nausea, making tirzepatide better tolerated than pure GLP-1 drugs for many users. In Vietnam, branded Mounjaro holds no marketing registration from the Drug Administration of Vietnam, so no hospital or licensed pharmacy has a registered supply of it to dispense and there is no hospital price to quote.4 Research-grade tirzepatide is widely available from peptide suppliers, sold by the vial, and how long a vial lasts depends on the dose. The tirzepatide Vietnam 2026 guide breaks down the registration position, research-grade pricing, and the Mounjaro vs generic decision. Tirzepatide is the choice for people who want a compound with FDA-approved efficacy behind it, obtained through the research-grade route.7

Semaglutide

Semaglutide is a GLP-1 receptor agonist that sparked the global weight loss peptide revolution and remains the most widely used option worldwide. The STEP clinical trials demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg dose, and its safety profile is the best understood of the four on this page, thanks to years of real-world use.2 Semaglutide is FDA-approved under two brand names: Ozempic (diabetes indication, 0.5 to 2mg doses, approved 2017)15 and Wegovy (obesity indication, up to 2.4mg, approved June 2021).816 In Vietnam, Ozempic holds a marketing registration and is listed by national pharmacy chains,17 though in practice it appears intermittently at pharmacies in District 1 and District 7 in HCMC, and occasionally in Hanoi expat areas. Research-grade semaglutide is widely available from peptide suppliers. The semaglutide Vietnam 2026 guide covers Ozempic vs research-grade sourcing, pharmacy hunting strategies, and pricing breakdowns. Semaglutide is the best choice for people new to GLP-1 peptides or anyone who wants the longest safety track record.

Cagrilintide

Cagrilintide is an amylin analogue that works through a completely different mechanism than GLP-1 agonists, making it a strong candidate for stacking rather than standalone use. Amylin is a hormone co-secreted with insulin that slows gastric emptying and suppresses appetite via different brain pathways than GLP-1. Phase 2 trials of cagrilintide alone showed approximately 10% weight loss, but the real promise is in combination therapy, Novo Nordisk is currently testing cagrilintide + semaglutide combinations in Phase 3 trials with early data suggesting additive effects beyond either drug alone.9 In Vietnam, cagrilintide is not available at any pharmacy or hospital and remains investigational globally. Research-grade cagrilintide is sold by the vial, but fewer suppliers stock it than the GLP-1 options. Locally it is reported mainly in combination with semaglutide or tirzepatide rather than on its own. Phase 3 trials test it mostly with semaglutide, and also on its own.

Disclaimer: this is general education, not medical advice and not a dosing recommendation.

Best peptide for weight loss and fat loss in 2026

What is the best peptide for weight loss or fat loss? Ranked by the mean body-weight reduction reported in their published obesity trials, retatrutide sits at the top: its Phase 2 trial in adults with obesity recorded 24.2% average reduction over 48 weeks at the 12mg dose (New England Journal of Medicine, 2023).5 Tirzepatide reached over 20% at the top 15mg dose over 72 weeks in the SURMOUNT-1 trial (NEJM, 2022), and semaglutide 14.9% over 68 weeks in STEP 1 (NEJM, 2021).3 So by trial effect size retatrutide is the strongest of the four, but it is still an investigational Phase 3 compound with no FDA approval,19 whereas tirzepatide and semaglutide are approved.1316 This is education about what the trials measured, not a recommendation to take anything; the dose that fits a given person belongs with a licensed prescriber.

What is the best peptide for fat burning? Retatrutide is the only one of these four that adds glucagon-receptor agonism on top of GLP-1 and GIP, and glucagon agonism is associated with raised energy expenditure and fat oxidation; in its Phase 2 trial (NEJM, 2023) this contributed to a 24.2% average body-weight reduction over 48 weeks at the1 12mg dose. It is worth being precise about what "fat burning" means in this data: the weight and fat-mass loss in these trials in adults with obesity is driven mainly by reduced appetite and calorie intake, not by a targeted fat-burner effect, so results reflect an overall energy deficit rather than spot fat loss. Some people describe that lower appetite as fewer nagging thoughts about food, a lay idea that researchers only began to score in 2025.

Best peptides for fat loss and weight loss in 2025 and 2026? The compounds with the strongest published weight-loss data heading into 2026 are the three incretin agonists on this page, retatrutide, tirzepatide, and semaglutide, plus the amylin analogue cagrilintide, which is studied mostly in combination with semaglutide rather than alone. Their standing has not changed between 2025 and 2026: retatrutide remains Phase 3 and unapproved, tirzepatide and semaglutide stay FDA-approved, and cagrilintide stays investigational.14 Retatrutide now has phase 3 data on top of its 24.2% phase 2 figure published in NEJM in 2023: in TRIUMPH-1, the New England Journal of Medicine reported -25.0% at the 12 mg trial dose versus -3.9% on placebo over 80 weeks for the treatment-regimen estimand (trial dose, not a recommendation), from a separate trial, not a head to head with the others.

Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026

Disclaimer: this is general education, not medical advice and not a dosing recommendation.

Where to source in Vietnam

There are three main routes for getting GLP-1 peptides in Vietnam, and which one makes sense depends on your priorities around cost, convenience, medical supervision, and compound selection. The international hospital route gives you registered branded drugs, in practice Ozempic, with full medical oversight, but your options are limited to whatever happens to be in stock and registered. [10] The pharmacy hunting route is hit-or-miss, Ozempic appears intermittently at pharmacies in District 1 and District 7 in HCMC and occasionally in Hanoi expat areas, but availability fluctuates wildly and you're still limited to branded semaglutide. The research-grade supplier route is where most informed expats and locals land because it offers the best combination of reliability and compound selection.

Research-grade peptide suppliers ship directly to Vietnam with cold-chain logistics, usually via DHL or FedEx with gel ice packs and temperature monitoring. The product arrives as lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before use. The key things to verify before ordering: third-party COA (certificate of analysis) showing purity and actual peptide content, proper cold-chain shipping with temperature monitoring, clear reconstitution instructions, and responsive customer service via WhatsApp or Zalo. The community-verified supplier list tracks which suppliers Vietnam-based users actually trust, with notes on COA quality, shipping reliability, and customer service responsiveness. The buying peptides in Vietnam guide walks through the full research-grade sourcing process step by step. Our supply partner's lab-tested research vials and their third-party batch certificates are listed in the full Peptara Labs catalog.

COA verification is critical because research-grade peptides vary wildly in quality. A proper COA comes from an independent third-party lab (not the supplier's in-house lab), shows HPLC purity testing with a clear chromatogram, lists actual peptide content in milligrams (not just percentages), and includes the specific batch number that matches your vial. Red flags include COAs with no batch numbers, suspiciously perfect 99%+ purity claims with no supporting chromatogram, or suppliers with no published batch certificate you can check before you buy. [11] The COA verification guide explains how to read HPLC chromatograms and spot fake certificates. For cold-chain shipping specifics and what to do if your peptides arrive warm, check the cold-chain logistics FAQ in the buying guide.

Get started

If you've decided which peptide makes sense for your situation, the next step is running the numbers on your expected timeline. The retatrutide weight loss calculator projects a trajectory from your starting stats using a Mifflin-St Jeor energy balance plus a conservative 0.5% of body weight per week assumption, which is our own figure and not one the Phase 2 trial reported. That tool models retatrutide only. Tirzepatide and semaglutide trials report smaller mean reductions, so do not read these projections across compounds. Once you know your timeline, browse the community-verified supplier list to find suppliers with strong Vietnam track records. Look for COA transparency, cold-chain shipping with temperature monitoring, and active customer support via WhatsApp or Zalo. Dosing decisions belong with a licensed prescriber; what the education emphasises is that GLP-1 protocols start low and build gradually, and that response is judged over weeks.

Calculate

Sources

Entries marked ° are cited from the publisher, but our checker could not retrieve the page to confirm the wording.

  1. 1.nejm.org / doi / full / 10.1056 / NEJMoa2301972°
  2. 2.PubMed PMID 33567185
  3. 3.PubMed PMID 35658024
  4. 4.vietnamnet.vn / but tiem giam can chua duoc cap phep o viet nam 2532258
  5. 5.PubMed PMID 37366315
  6. 6.nejm.org / doi / full / 10.1056 / NEJMoa2206038°
  7. 7.fda.gov / news events / press announcements / fda approves new medication chronic weight management
  8. 8.accessdata.fda.gov / drugsatfda docs / label / 2026 / 215256s033lbl.pdf°
  9. 9.PubMed PMID 40544433
  10. 10.DailyMed, OZEMPIC (semaglutide) label: a GLP-1 receptor agonist indicated for adults with type 2 diabetes. Read 30 October 2026
  11. 11.PubMed PMID 39509151
  12. 12.PubMed PMID 2305711
  13. 13.US FDA prescribing information for MOUNJARO (tirzepatide) injection: "Initial U.S. Approval: 2022"
  14. 14.PubMed PMID 39649698
  15. 15.DailyMed, OZEMPIC (semaglutide) injection label: "Initial U.S. Approval: 2017", titration to 0.5 mg, 1 mg and 2 mg once weekly
  16. 16.Drugs@FDA, NDA 215256 (WEGOVY, semaglutide): "06/04/2021 ORIG-1 Approval PRIORITY"
  17. 17.FPT Long Chau: Ozempic 0.25mg/0.5mg Novo Nordisk, Vietnamese registration number 570410174600, listed at 4,750,000 VND per box
  18. 18.Coskun T, Urva S, Roell WC, et al. Cell Metab (2022). PMID 35985340. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist, from discovery to clinical proof of concept
  19. 19.ClinicalTrials.gov NCT05882045, retrieved 22 August 2026: "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", Phase 3
  20. 20.Drug Administration of Vietnam public drug registry, queried 22 August 2026: zero registered products for retatrutide, against 1 for semaglutide (Ozempic) as the control
  21. 21.TRIUMPH-1, New England Journal of Medicine, 29 September 2026